Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis

NCT06519591 Phase 2 RECRUITING

In this phase 2 study, we combined Cadonilimab, LM-302, and S-1 combined with intraperitoneal infusion of paclitaxel as regimen to treat gastric cancer patients with peritoneal metastasis.

Details

Lead sponsor	Ruijin Hospital
Phase	Phase 2
Status	RECRUITING
Enrolment	40
Start date	2025-02-25
Completion	2026-12

Conditions

• Gastric Cancer Stage IV
• Peritoneal Metastases

Interventions

• Cadonilimab, LM-302, S-1, paclitaxel

Primary outcomes

• 1-year survival rate — up to 24 months

Countries

China